E board review in Breast Cancer February 2008 Reading List

Article

html>body {font-size: small;}a:link {color: #990000}a:visited {color: #990000;}a:hover {color: #cccccc}table td {padding: 0pt; border-width: 0; vertical-align: top; font-family: arial, helvetica, verdana, sans-serif;}td#footer {background: #ccffcc; padding: 10px; font: normal 90% arial, helvetica, sans-serif; vertical-align: middle;}td#sponsor a {color: #FFF;}td#sponsor a:visited {color: #FFF;}td#sponsor {background: #333399; width: 625px; height: 10px; padding: 5px; font: 100% verdana, arial, helvetica ; color: #ffffff;}td#date {background: #cccccc; width: 625px; height: 10px; padding: 5px 5px; font: bold 110% verdana, arial, helvetica ; color: #000000;}b#ge {font: italic bold 100% verdana, arial, helvetica;}td#content {font: normal 10pt/14pt arial, verdana, helvetica; padding: 5px;}h3 {font: bold 120% verdana, arial, helvetica, sans-seif; color: #000000; padding: 5px;}h4 {font: normal 120% verdana, arial, helvetica, sans-seif; color: #000000;}h5 {font: times,serif; color: #990000;}div#links {position: absolute; top: 40px left: 0; width: 200px;}div#links a {color: #ffcc00; display: block; padding: 5px 10px; margin: 0 0 2px; border-width=0; text-align: center; font: bold 17px/17px sans-serif; text-decoration: none;}div#links a:visited:hover {color: #cccccc;}a.bluelink:link, a.bluelink:visited { color:#036; font:normal 10px "Lucida Grande", "Lucida Sans Unicode", verdana, lucida, sans-serif; text-decoration :underline;}.menunav { border-top: 2px solid #5A6565; background: #919898; padding: 3px 3px 3px 3px; border-bottom: 2px solid #ffffff; }.menunav_selected { color: #FFFFFF;background: #B2B7B7; border-top: 2px solid #5A6565; padding: 3px 3px 3px 3px; border-bottom: 2px solid #ffffff; }.menunav_selected_sub { background: #D3D6D6; padding: 3px 3px 3px 15px; }div#menu_menu {width: 90%;border: 1px solid #333;padding: 10px 10px 0px 10px;}div#menu_menu a { padding: 3px 0 3px 0; border-top: 1px solid #990000; text-decoration: none;color:#000; font-family:arial, helvetica, sans-serif; font-size: x-small; display: block; text-align: left; vertical-align: bottom;}div#menu_menu a:hover {color: #FFFFFF;background: #990000;}#menu_menu LI { margin: 10; padding: 0; display: inline; border-bottom: 2px solid #ffffff; }div#apply {width: 100%;border: 0px solid #333;padding: 0px 0px 0px 0px;background: #008A45;}div#apply a { border-top: 1px solid #990000; text-decoration: none;color:#FFF0D0; font-family:arial, helvetica, sans-serif; font-size: x-small; display: block; text-align: left; vertical-align: bottom;}div#apply a:hover {color: #FFFFFF;background: #990000;}#apply LI { margin: 10; padding: 0; display: inline; border-bottom: 2px solid #ffffff; } #menurightcolumn { width: 220px; \width: 240px; w\idth: 220px; padding: 10px; text-align: left; margin: 0px; float: right; }.clearer {clear: both;}ol {list-style-type: decimal; margin-left:20px;}

 

Suggested Reading List

Print Entire Reading List

Reducing Risk/Increasing Survival
(Questions 1–7)

Adjuvant Therapy
(Questions 8–13)

Treatment Results
(Questions 14–20)

Advanced and Recurrent Disease
(Questions 21–32)

Breast Cancer Subtypes
(Questions 33–36)

Recent Videos
Ablative technology may generate an immune response that can be enhanced via injected immunotherapy in patients with solid tumors.
Vinay K. Puduvalli, MD, is featured in this series.
Medical use of AI increases every day, and in the future, will be exponentially greater and many forms of treatment will be improved, according to Russell C. Langan, MD, FACS, FSSO.
Related Content